Загрузка...

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

Cytarabine resistance characterizes relapsed and refractory acute myelogenous leukemia (AML). Restoration of cytarabine sensitivity can potentially improve treatment outcome in this setting. Acquired hypermethylation of gene promoters and associated silencing of gene expression has been implicated i...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: BORTHAKUR, GAUTAM, HUANG, XUELIN, KANTARJIAN, HAGOP, FADERL, STEFAN, RAVANDI, FARHAD, FERRAJOLI, ALESSANDRA, TORMA, RITVA, MORRIS, GAIL, BERRY, DONALD, ISSA, JEAN-PIERRE
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2876330/
https://ncbi.nlm.nih.gov/pubmed/20017599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428190903318329
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!